Roivant公布Imvt-1402在皮肤红斑狼疮概念验证研究中的顶线结果

美股速递
Sep 23

Roivant Sciences Ltd.今日宣布,其针对皮肤红斑狼疮(CLE)的在研药物Imvt-1402已完成概念验证研究,并取得顶线结果。该项研究的数据表明,该药物在主要疗效终点上展现出具有临床意义的改善,同时安全性与耐受性表现良好。公司表示,详细数据将在未来的医学会议上予以公布。这一进展为皮肤红斑狼疮患者群体带来了新的治疗希望,也标志着Roivant在炎症与免疫领域的研发管线又迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10